When to take profits is a tricky but important decision.
The stock looks ready to break out.
It is no pipedream that the stock could trade to $240.

Small-Cap Friday's Little Gem Real Money Pro($)

One small pharmaceutical company has big potential.
JNJ provides low-risk, good income and modest appreciation.
Watch this leadership group that's been lagging.

Pfizer Pullback Begins Real Money Pro($)

A continued fade back down offers a buying opportunity.
Fibrocell Science and Prothena have several 'shots on goal.'
A huge political headwind has been removed for this pharma.
The biotech has a great record growing earnings and shareholder value.

Columnist Conversations

Reports on Tuesday. I am getting a little concerned on how the 2015 guidance will come in.
Soz doing some more good stuff on retail today-- I loved the JCP piece.. Remember you can follow a writer now ...
Despite a big upgrade from Credit Suisse(from Neutral to Outperform)FDX is relatively flat today. The st...
The Market Vectors Gold Miners ETF (GDX) chart continues to exhibit characteristics of a classic cup-and-handl...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.